Hepatic Disease in HIV-Infected Patients
Summary
- Rates of noncirrhotic portal hypertension have ranged from 1%[Maida 2006] to 8% of HIV-infected patients[Mallet 2007]
- No single etiology or characteristic histologic finding has been identified to explain noncirrhotic portal hypertension in HIV-infected patients without HBV or HCV infection
- FDA published an alert about the risk of noncirrhotic portal hypertension in patients taking didanosine and added new information to the prescription label[FDA 2010]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content